Investing.com - Financial Markets Worldwide

iRhythm Technologies stock hits 52-week high at 158.48 USD

Published 01/08/2025, 14:34
iRhythm Technologies stock hits 52-week high at 158.48 USD
IRTC
-3.38%

Shares of iRhythm Technologies Inc (NASDAQ:IRTC). reached a 52-week high, trading at 158.48 USD. This milestone comes amid a notable 1-year change, with the stock appreciating by 89.74%. The company, now valued at $4.48 billion, has demonstrated strong fundamentals with revenue growth of 20.54% and a healthy gross profit margin of 69.39%. InvestingPro analysis reveals 12 key investment insights for this stock. The surge in iRhythm’s stock price reflects the company’s robust performance and investor confidence over the past year. The company maintains strong liquidity with a current ratio of 5.71, and has received a "GOOD" overall Financial Health rating from InvestingPro. As the company continues to innovate in the field of digital healthcare, this upward trajectory highlights the growing interest and potential in their offerings. The recent high underscores a significant recovery and growth phase for iRhythm Technologies in the competitive medical technology sector, though current trading levels suggest the stock may be overvalued according to InvestingPro’s Fair Value analysis.

In other recent news, iRhythm Technologies Inc. reported its financial results for the second quarter of 2025, surpassing analysts’ expectations. The company announced an adjusted net loss of $0.32 per share, which was better than the anticipated loss of $0.51 per share. Revenue for the quarter reached $186.7 million, exceeding forecasts and representing a 26.1% increase compared to the same period last year. These results highlight strong revenue growth for iRhythm. There were no major stock movements following the earnings announcement. The company’s performance in the second quarter reflects a positive trend in its financial health. Analysts have taken note of iRhythm’s ability to outperform expectations. This marks a significant achievement for iRhythm in the current fiscal year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.